I usually don’t pay much attention to the ads that play before YouTube videos, but this one held my interest long enough to watch the whole thing. Here it is (please do watch it, since it’s only about a minute and kind of interesting):
Slope of Hope Blog Posts
Slope initially began as a blog, so this is where most of the website’s content resides. Here we have tens of thousands of posts dating back over a decade. These are listed in reverse chronological order. Click on any category icon below to see posts tagged with that particular subject, or click on a word in the category cloud on the right side of the screen for more specific choices.
Silver 2011, Dow 2017
This is not a top call. My target was Dow 21,000 and this pig blew through it and flew to 21,115. This is a comparison of one bubble to another a potential other.
In 2011 silver put on an amazing run. First, it dropped and crashed the SMA 50 at the beginning of the year. Then it rebounded, became over bought by RSI (and distance from the SMA 50), tested the short-term EMA 20 and then went all Sky Lab, making a 2nd strenuously overbought reading on RSI. Then… kerplunk.
Biotechs Breaking Out
By Harry Boxer
Here are four biotech stocks breaking out on positive developments related to their drugs.
bluebird bio, Inc. (BLUE) has popped about 20 points in a week to Wednesday’s close of $92.80. On Wednesday alone, it rose $5.15 on over 1 million shares traded, closing just a dime off the high. The company announced publication of a case study on the first patient with severe sickle cell disease treated with its gene therapy product. The stock has far surpassed our initial target of $85 and is closing in on the next target of $95. There’s a possibility it may run up to the $106-7 range, last reached in October 2015, which is the new, near-term target. Short interest of 12.9 times its average volume could fuel the move as shorts cover on an advance.
Esperion Therapeutics, Inc. (ESPR) followed through for another $4.23 to $30.44 Wednesday on 2.2 million shares. Just a month ago, the stock was under $11, but investors appear to be hopeful that the biotech company’s lead drug for treating high cholesterol is more likely to win approval under President Trump. The stock is a little long in the tooth short-term and may need to rest and pullback before its next move. However, after the stock dropped from a high of nearly $119 in March 2015 to under $10 in late June 2016, it based for 7 months, and has now broken well out of that base and is looking higher.
